Skip to content

Reflectance Microscopic changes of Vulvar Lichen Sclerosus after 5-Aminolevulinic Acid Photodynamic Therapy

Reflectance Microscopic changes of Vulvar Lichen Sclerosus after 5-Aminolevulinic Acid Photodynamic Therapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104192
Enrollment
Unknown
Registered
2025-06-12
Start date
2024-10-13
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvar Lichen Sclerosus

Interventions

Health group:No
Photodynamic therapy group:Patients were treated within 3-7d after menstruation, and menopausal patients were scheduled for treatment after enrollment.After skin preparation, 20% photosensitizer (5-A
Mometasone Convalescence Treatment Group:Patients were treated with mometasone furoate cream (avoiding menstruation) applied thinly in a 0.5 cm area in and around the skin lesion site (avoiding menstr

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Female patients; 2. 18 <= age <= 65 years old; 3. Those meet the diagnostic criteria of vulvar lichen sclerosus and excludes atypical lesions and malignant tumors; 4. Patients with complete clinical data, good compliance, and regular follow-up during and after treatment.

Exclusion criteria

Exclusion criteria: 1. Persons who are allergic to the study drug; 2. Those who suffer from photosensitizing diseases; 3. Those who used steroid hormones or immune inhibitor 3 months before treatment; 4. Pregnant, lactating women and prepubescent children; 5. Reproductive tract infection; 6.Patients with severe cardiovascular or liver and kidney diseases.

Design outcomes

Primary

MeasureTime frame
Itching degree;Skin elasticity;Skin color;Lesion range;MIF concentration in serum;Skin CT imaging image;

Countries

China

Contacts

Public ContactWang Xibo

Weifang People's Hospital

wangxibowf@163.com+86 134 5564 5180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026